Charleston Laboratories

Executive Summary

Charleston Laboratories is a US-based biopharmaceutical company founded in 2004, specializing in prescription pain medications with integrated technologies to reduce side effects like nausea and vomiting. Its lead candidate, CL-108, is a fixed-dose combination targeting opioid-induced nausea and vomiting (OINV), a significant unmet need in acute pain management. The company has developed a proprietary formulation that combines an opioid with an antiemetic to improve patient compliance and outcomes. CL-108 is currently in clinical development, and the company is seeking to address the limitations of current opioid therapies by mitigating one of the most common and distressing side effects. With a focus on small molecules, Charleston Laboratories represents a niche player in the pain management space, differentiating itself through a patient-centric approach to opioid therapy. The company's success hinges on the clinical and regulatory advancement of CL-108, which could offer a competitive advantage if approved.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase 3 clinical trials for CL-10860% success
• Q2 2026Regulatory meeting (End-of-Phase 2) with FDA70% success
• Q4 2026Publication of Phase 2 clinical data for CL-10865% success